JP2005507669A - ２５９４３を用いる細胞増殖障害の処置および診断のための方法および組成物 - Google Patents

Info

Publication number

JP2005507669A

JP2005507669A JP2003540378A JP2003540378A JP2005507669A JP 2005507669 A JP2005507669 A JP 2005507669A JP 2003540378 A JP2003540378 A JP 2003540378A JP 2003540378 A JP2003540378 A JP 2003540378A JP 2005507669 A JP2005507669 A JP 2005507669A

Authority

JP

Japan

Prior art keywords

cell

protein

expression

cells

nucleic acid

Prior art date

2001-10-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 211
• 239000000203 mixture Substances 0.000 title claims abstract description 34
• 230000002062 proliferating effect Effects 0.000 title claims abstract description 32
• 238000011282 treatment Methods 0.000 title abstract description 49
• 238000003745 diagnosis Methods 0.000 title abstract description 7
• 230000014509 gene expression Effects 0.000 claims abstract description 171
• 230000000694 effects Effects 0.000 claims abstract description 154
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 152
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 146
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 145
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 145
• 150000001875 compounds Chemical class 0.000 claims abstract description 99
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 81
• 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 68
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 63
• 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 50
• 229920001184 polypeptide Polymers 0.000 claims abstract description 49
• 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 46
• 208000020816 lung neoplasm Diseases 0.000 claims abstract description 42
• 206010006187 Breast cancer Diseases 0.000 claims abstract description 40
• 230000004663 cell proliferation Effects 0.000 claims abstract description 40
• 206010009944 Colon cancer Diseases 0.000 claims abstract description 27
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 24
• 201000005202 lung cancer Diseases 0.000 claims abstract description 24
• 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 22
• 208000035269 cancer or benign tumor Diseases 0.000 claims abstract description 12
• 210000004027 cell Anatomy 0.000 claims description 282
• 238000012360 testing method Methods 0.000 claims description 56
• 230000000692 anti-sense effect Effects 0.000 claims description 46
• 210000001072 colon Anatomy 0.000 claims description 42
• 210000000481 breast Anatomy 0.000 claims description 18
• 210000001672 ovary Anatomy 0.000 claims description 16
• 230000010261 cell growth Effects 0.000 claims description 9
• 210000005265 lung cell Anatomy 0.000 claims description 8
• 230000001594 aberrant effect Effects 0.000 claims description 5
• 238000009472 formulation Methods 0.000 claims description 5
• 230000002159 abnormal effect Effects 0.000 abstract description 16
• 108090000623 proteins and genes Proteins 0.000 description 316
• 102000004169 proteins and genes Human genes 0.000 description 219
• 235000018102 proteins Nutrition 0.000 description 212
• 108020004414 DNA Proteins 0.000 description 87
• 239000000523 sample Substances 0.000 description 86
• 201000010099 disease Diseases 0.000 description 77
• 125000003729 nucleotide group Chemical group 0.000 description 65
• 208000035475 disorder Diseases 0.000 description 62
• 239000002773 nucleotide Substances 0.000 description 61
• 108020004999 messenger RNA Proteins 0.000 description 57
• 206010028980 Neoplasm Diseases 0.000 description 55
• 238000003556 assay Methods 0.000 description 55
• 239000003814 drug Substances 0.000 description 50
• 239000003795 chemical substances by application Substances 0.000 description 46
• 125000003275 alpha amino acid group Chemical group 0.000 description 44
• 210000004881 tumor cell Anatomy 0.000 description 43
• 238000009396 hybridization Methods 0.000 description 41
• 239000012634 fragment Substances 0.000 description 40
• 210000001519 tissue Anatomy 0.000 description 40
• 229940079593 drug Drugs 0.000 description 38
• 230000035772 mutation Effects 0.000 description 38
• 108010023546 Aspartylglucosylaminase Proteins 0.000 description 36
• 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 35
• 230000001105 regulatory effect Effects 0.000 description 33
• 239000013598 vector Substances 0.000 description 33
• 238000004458 analytical method Methods 0.000 description 32
• 239000013604 expression vector Substances 0.000 description 31
• 235000001014 amino acid Nutrition 0.000 description 29
• 208000037841 lung tumor Diseases 0.000 description 29
• 102000037865 fusion proteins Human genes 0.000 description 28
• 108020001507 fusion proteins Proteins 0.000 description 28
• 238000005259 measurement Methods 0.000 description 28
• 238000001514 detection method Methods 0.000 description 27
• 239000000758 substrate Substances 0.000 description 27
• 102000004190 Enzymes Human genes 0.000 description 26
• 108090000790 Enzymes Proteins 0.000 description 26
• 229940088598 enzyme Drugs 0.000 description 26
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 25
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
• 229940024606 amino acid Drugs 0.000 description 24
• 150000001413 amino acids Chemical class 0.000 description 24
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
• 230000000295 complement effect Effects 0.000 description 21
• 230000001225 therapeutic effect Effects 0.000 description 21
• 125000000539 amino acid group Chemical group 0.000 description 20
• 230000000381 tumorigenic effect Effects 0.000 description 20
• KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 19
• 238000003752 polymerase chain reaction Methods 0.000 description 19
• 230000027455 binding Effects 0.000 description 18
• 229950006344 nocodazole Drugs 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• 231100000588 tumorigenic Toxicity 0.000 description 18
• 108091034117 Oligonucleotide Proteins 0.000 description 17
• 238000006243 chemical reaction Methods 0.000 description 17
• 210000004185 liver Anatomy 0.000 description 17
• 230000004044 response Effects 0.000 description 17
• 241001465754 Metazoa Species 0.000 description 16
• 208000024891 symptom Diseases 0.000 description 16
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
• 239000012472 biological sample Substances 0.000 description 15
• 230000004927 fusion Effects 0.000 description 15
• 239000000463 material Substances 0.000 description 15
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 14
• 108090000994 Catalytic RNA Proteins 0.000 description 14
• 102000053642 Catalytic RNA Human genes 0.000 description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 description 14
• 230000001640 apoptogenic effect Effects 0.000 description 14
• 239000002609 medium Substances 0.000 description 14
• 238000003199 nucleic acid amplification method Methods 0.000 description 14
• 108091092562 ribozyme Proteins 0.000 description 14
• 150000003384 small molecules Chemical class 0.000 description 14
• 230000003321 amplification Effects 0.000 description 13
• 238000010171 animal model Methods 0.000 description 13
• 239000002299 complementary DNA Substances 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 230000012010 growth Effects 0.000 description 13
• 238000000338 in vitro Methods 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 210000004072 lung Anatomy 0.000 description 13
• 230000002611 ovarian Effects 0.000 description 13
• 239000013615 primer Substances 0.000 description 13
• 210000002966 serum Anatomy 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 206010027476 Metastases Diseases 0.000 description 12
• 108700020796 Oncogene Proteins 0.000 description 12
• NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 12
• SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 12
• 230000022131 cell cycle Effects 0.000 description 12
• 239000000975 dye Substances 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 239000012528 membrane Substances 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 238000007423 screening assay Methods 0.000 description 12
• 239000011780 sodium chloride Substances 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 11
• 230000004071 biological effect Effects 0.000 description 11
• 210000004408 hybridoma Anatomy 0.000 description 11
• 238000012216 screening Methods 0.000 description 11
• 238000013518 transcription Methods 0.000 description 11
• 230000035897 transcription Effects 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 description 10
• 238000003149 assay kit Methods 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 230000037396 body weight Effects 0.000 description 10
• -1 carbon amino acid Chemical class 0.000 description 10
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 201000000050 myeloid neoplasm Diseases 0.000 description 10
• 238000003259 recombinant expression Methods 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 229920001817 Agar Polymers 0.000 description 9
• 239000008272 agar Substances 0.000 description 9
• 231100000504 carcinogenesis Toxicity 0.000 description 9
• 238000003776 cleavage reaction Methods 0.000 description 9
• 238000007398 colorimetric assay Methods 0.000 description 9
• 238000007901 in situ hybridization Methods 0.000 description 9
• 210000004698 lymphocyte Anatomy 0.000 description 9
• 230000002503 metabolic effect Effects 0.000 description 9
• 230000002974 pharmacogenomic effect Effects 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 102000053602 DNA Human genes 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 8
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 125000003164 beta-aspartyl group Chemical group 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 230000002163 immunogen Effects 0.000 description 8
• 238000010348 incorporation Methods 0.000 description 8
• 238000002372 labelling Methods 0.000 description 8
• 239000011159 matrix material Substances 0.000 description 8
• 230000004481 post-translational protein modification Effects 0.000 description 8
• 238000012545 processing Methods 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 230000007017 scission Effects 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 238000010561 standard procedure Methods 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
• 208000005623 Carcinogenesis Diseases 0.000 description 7
• 231100000750 In vitro toxicology Toxicity 0.000 description 7
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
• 102000040945 Transcription factor Human genes 0.000 description 7
• 108091023040 Transcription factor Proteins 0.000 description 7
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 7
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 229960005261 aspartic acid Drugs 0.000 description 7
• 230000036952 cancer formation Effects 0.000 description 7
• 238000002737 cell proliferation kit Methods 0.000 description 7
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
• 230000034994 death Effects 0.000 description 7
• 231100000517 death Toxicity 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 230000009401 metastasis Effects 0.000 description 7
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
• 230000006820 DNA synthesis Effects 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 108010070675 Glutathione transferase Proteins 0.000 description 6
• 102000005720 Glutathione transferase Human genes 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 6
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
• 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 6
• 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 108700008625 Reporter Genes Proteins 0.000 description 6
• 208000009956 adenocarcinoma Diseases 0.000 description 6
• 235000003704 aspartic acid Nutrition 0.000 description 6
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
• 101150042537 dld1 gene Proteins 0.000 description 6
• 210000000981 epithelium Anatomy 0.000 description 6
• 238000010195 expression analysis Methods 0.000 description 6
• 102000018358 immunoglobulin Human genes 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 210000002381 plasma Anatomy 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 239000012064 sodium phosphate buffer Substances 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
• 102000015735 Beta-catenin Human genes 0.000 description 5
• 108060000903 Beta-catenin Proteins 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 108091033380 Coding strand Proteins 0.000 description 5
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 108090000288 Glycoproteins Proteins 0.000 description 5
• 102000003886 Glycoproteins Human genes 0.000 description 5
• 101710163270 Nuclease Proteins 0.000 description 5
• 108020004511 Recombinant DNA Proteins 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 229960001230 asparagine Drugs 0.000 description 5
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 229960004316 cisplatin Drugs 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 239000012894 fetal calf serum Substances 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 230000007062 hydrolysis Effects 0.000 description 5
• 238000006460 hydrolysis reaction Methods 0.000 description 5
• 238000010249 in-situ analysis Methods 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 102000054765 polymorphisms of proteins Human genes 0.000 description 5
• 230000000069 prophylactic effect Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 238000012163 sequencing technique Methods 0.000 description 5
• 238000003860 storage Methods 0.000 description 5
• 230000001360 synchronised effect Effects 0.000 description 5
• 229940104230 thymidine Drugs 0.000 description 5
• JJVXHDTWVIPRBZ-VKHMYHEASA-N (2r)-2-[carboxy(methyl)amino]-3-sulfanylpropanoic acid Chemical compound OC(=O)N(C)[C@@H](CS)C(O)=O JJVXHDTWVIPRBZ-VKHMYHEASA-N 0.000 description 4
• 208000003200 Adenoma Diseases 0.000 description 4
• 108700028369 Alleles Proteins 0.000 description 4
• 101150071279 Apc gene Proteins 0.000 description 4
• 206010003445 Ascites Diseases 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 108050006400 Cyclin Proteins 0.000 description 4
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 102000001554 Hemoglobins Human genes 0.000 description 4
• 108010054147 Hemoglobins Proteins 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 239000005089 Luciferase Substances 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
• 238000012408 PCR amplification Methods 0.000 description 4
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 230000004075 alteration Effects 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 239000000074 antisense oligonucleotide Substances 0.000 description 4
• 238000012230 antisense oligonucleotides Methods 0.000 description 4
• 235000009582 asparagine Nutrition 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 230000024245 cell differentiation Effects 0.000 description 4
• 238000001516 cell proliferation assay Methods 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000003184 complementary RNA Substances 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 231100000599 cytotoxic agent Toxicity 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 230000004077 genetic alteration Effects 0.000 description 4
• 231100000118 genetic alteration Toxicity 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 150000002484 inorganic compounds Chemical class 0.000 description 4
• 229910010272 inorganic material Inorganic materials 0.000 description 4
• 210000003292 kidney cell Anatomy 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 206010061289 metastatic neoplasm Diseases 0.000 description 4
• 230000033607 mismatch repair Effects 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 238000011580 nude mouse model Methods 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 150000002894 organic compounds Chemical class 0.000 description 4
• 239000005022 packaging material Substances 0.000 description 4
• 239000000816 peptidomimetic Substances 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 238000011269 treatment regimen Methods 0.000 description 4
• 230000005740 tumor formation Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 238000002689 xenotransplantation Methods 0.000 description 4
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 206010001233 Adenoma benign Diseases 0.000 description 3
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• 108020005544 Antisense RNA Proteins 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 239000003155 DNA primer Substances 0.000 description 3
• 230000004568 DNA-binding Effects 0.000 description 3
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
• 108010092160 Dactinomycin Proteins 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• 108060006698 EGF receptor Proteins 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
• 108091092724 Noncoding DNA Proteins 0.000 description 3
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 108010083644 Ribonucleases Proteins 0.000 description 3
• 102000006382 Ribonucleases Human genes 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 229940041181 antineoplastic drug Drugs 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 239000013068 control sample Substances 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000003828 downregulation Effects 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 230000001747 exhibiting effect Effects 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000001476 gene delivery Methods 0.000 description 3
• 230000007614 genetic variation Effects 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 229950006780 n-acetylglucosamine Drugs 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 239000002853 nucleic acid probe Substances 0.000 description 3
• 231100000590 oncogenic Toxicity 0.000 description 3
• 230000002246 oncogenic effect Effects 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 229940117953 phenylisothiocyanate Drugs 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000002731 protein assay Methods 0.000 description 3
• 239000012857 radioactive material Substances 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000001509 sodium citrate Substances 0.000 description 3
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 210000004988 splenocyte Anatomy 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 238000000108 ultra-filtration Methods 0.000 description 3
• SBRYFUVVWOMLLP-VKHMYHEASA-N (2s)-2-amino-4-methoxy-4-oxobutanoic acid Chemical compound COC(=O)C[C@H](N)C(O)=O SBRYFUVVWOMLLP-VKHMYHEASA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 208000004804 Adenomatous Polyps Diseases 0.000 description 2
• 208000005748 Aggressive Fibromatosis Diseases 0.000 description 2
• 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 108010062580 Concanavalin A Proteins 0.000 description 2
• 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
• 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 2
• 239000003298 DNA probe Substances 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 102000016911 Deoxyribonucleases Human genes 0.000 description 2
• 108010053770 Deoxyribonucleases Proteins 0.000 description 2
• 206010058314 Dysplasia Diseases 0.000 description 2
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 108091027305 Heteroduplex Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• 206010027457 Metastases to liver Diseases 0.000 description 2
• 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
• 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
• YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 description 2
• HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
• 102400000058 Neuregulin-1 Human genes 0.000 description 2
• 108090000556 Neuregulin-1 Proteins 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010001441 Phosphopeptides Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 210000002798 bone marrow cell Anatomy 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000012830 cancer therapeutic Substances 0.000 description 2
• 230000000711 cancerogenic effect Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 231100000357 carcinogen Toxicity 0.000 description 2
• 239000003183 carcinogenic agent Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 230000004732 colorectal carcinogenesis Effects 0.000 description 2
• 238000002742 combinatorial mutagenesis Methods 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 238000001952 enzyme assay Methods 0.000 description 2
• 210000000267 erythroid cell Anatomy 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000012997 ficoll-paque Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 238000007421 fluorometric assay Methods 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 125000003147 glycosyl group Chemical group 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 210000003016 hypothalamus Anatomy 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000002751 lymph Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 230000037311 normal skin Effects 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 210000000963 osteoblast Anatomy 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 230000020477 pH reduction Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 238000006303 photolysis reaction Methods 0.000 description 2
• 230000015843 photosynthesis, light reaction Effects 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 238000007747 plating Methods 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 239000002987 primer (paints) Substances 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000014493 regulation of gene expression Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000002821 scintillation proximity assay Methods 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 231100000004 severe toxicity Toxicity 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000003153 stable transfection Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
• HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 238000012447 xenograft mouse model Methods 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• GKVYASWXBAODMQ-KOBWPYANSA-N (2S)-2-amino-4-[(3R,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-oxobutanoic acid Chemical compound N[C@@H](CC(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO)C(=O)O GKVYASWXBAODMQ-KOBWPYANSA-N 0.000 description 1
• FMHPSVZSLZOGKT-BYPYZUCNSA-N (2S)-2-amino-5-diazo-4-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)C=[N+]=[N-] FMHPSVZSLZOGKT-BYPYZUCNSA-N 0.000 description 1
• NLEBIOOXCVAHBD-YHBSTRCHSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-YHBSTRCHSA-N 0.000 description 1
• SHHIPKDJQYIJJF-QWRGUYRKSA-N (2s)-2-amino-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 SHHIPKDJQYIJJF-QWRGUYRKSA-N 0.000 description 1
• OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• GYJNVSAUBGJVLV-UHFFFAOYSA-N 3-(dimethylazaniumyl)propane-1-sulfonate Chemical compound CN(C)CCCS(O)(=O)=O GYJNVSAUBGJVLV-UHFFFAOYSA-N 0.000 description 1
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
• GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
• WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• 108700001666 APC Genes Proteins 0.000 description 1
• 230000002407 ATP formation Effects 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 102100027211 Albumin Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 description 1
• 102100033695 Anaphase-promoting complex subunit 13 Human genes 0.000 description 1
• 101710155999 Anaphase-promoting complex subunit 13 Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000002109 Argyria Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100031173 CCN family member 4 Human genes 0.000 description 1
• 101710137353 CCN family member 4 Proteins 0.000 description 1
• 101150010738 CYP2D6 gene Proteins 0.000 description 1
• 101100351256 Caenorhabditis elegans ccm-3 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 240000001432 Calendula officinalis Species 0.000 description 1
• 235000005881 Calendula officinalis Nutrition 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
• 241000252203 Clupea harengus Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 108010058546 Cyclin D1 Proteins 0.000 description 1
• 102100021906 Cyclin-O Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102100030497 Cytochrome c Human genes 0.000 description 1
• 108010075031 Cytochromes c Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020001738 DNA Glycosylase Proteins 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 102000028381 DNA glycosylase Human genes 0.000 description 1
• 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
• 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
• 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010059352 Desmoid tumour Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 230000010190 G1 phase Effects 0.000 description 1
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
• 230000010337 G2 phase Effects 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 206010071602 Genetic polymorphism Diseases 0.000 description 1
• VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 241000288105 Grus Species 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
• 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• ZTEDWFWBGPKUOD-VKHMYHEASA-N L-beta-aspartylglycine Chemical compound OC(=O)[C@@H](N)CC(=O)NCC(O)=O ZTEDWFWBGPKUOD-VKHMYHEASA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• WZNJWVWKTVETCG-YFKPBYRVSA-N L-mimosine Chemical compound OC(=O)[C@@H](N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-YFKPBYRVSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000015439 Lysosomal storage disease Diseases 0.000 description 1
• 101150110531 MLH1 gene Proteins 0.000 description 1
• 229910015837 MSH2 Inorganic materials 0.000 description 1
• 101150102506 MSH3 gene Proteins 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 206010027458 Metastases to lung Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 101150033433 Msh2 gene Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• LJTJIFJOYZJWSL-KEWYIRBNSA-N N-[(3R,4R,5S,6R)-2-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1(N)O LJTJIFJOYZJWSL-KEWYIRBNSA-N 0.000 description 1
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
• MCGXOCXFFNKASF-FMDGEEDCSA-N N-acetyl-beta-D-glucosaminylamine Chemical compound CC(=O)N[C@H]1[C@H](N)O[C@H](CO)[C@@H](O)[C@@H]1O MCGXOCXFFNKASF-FMDGEEDCSA-N 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 241000233805 Phoenix Species 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
• 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 108010066717 Q beta Replicase Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 108091006463 SLC25A24 Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 241000223892 Tetrahymena Species 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010066901 Treatment failure Diseases 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
• 240000006677 Vicia faba Species 0.000 description 1
• 235000010749 Vicia faba Nutrition 0.000 description 1
• 235000002098 Vicia faba var. major Nutrition 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• RJZZTNAWUTTWMJ-WYIOVZGUSA-N [(2r,3s,5s)-5-amino-2-[2-(4-methoxyphenyl)-2,2-diphenylethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphonamidous acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C[C@@H]1[C@@H](OP(N)O)C[C@](N)(N2C(NC(=O)C(C)=C2)=O)O1 RJZZTNAWUTTWMJ-WYIOVZGUSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 238000003916 acid precipitation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 230000009118 appropriate response Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 238000011717 athymic nude mouse Methods 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 108010056625 beta-aspartylglycine Proteins 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000000746 body region Anatomy 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000005773 cancer-related death Effects 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000010609 cell counting kit-8 assay Methods 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 238000002701 cell growth assay Methods 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 238000003570 cell viability assay Methods 0.000 description 1
• 238000012054 celltiter-glo Methods 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
• 238000012668 chain scission Methods 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 238000002038 chemiluminescence detection Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
• 229960002626 clarithromycin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 230000030944 contact inhibition Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 101150089829 csc-1 gene Proteins 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000013500 data storage Methods 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000012137 double-staining Methods 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000013399 early diagnosis Methods 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000001819 effect on gene Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000012246 gene addition Methods 0.000 description 1
• 238000011223 gene expression profiling Methods 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930182478 glucoside Natural products 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 235000019514 herring Nutrition 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000012482 interaction analysis Methods 0.000 description 1
• 238000009830 intercalation Methods 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 238000010829 isocratic elution Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 150000002527 isonitriles Chemical class 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 210000004558 lewy body Anatomy 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 238000010630 lipid peroxidation (MDA) assay Methods 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000000691 measurement method Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
• MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 1
• 229950002289 mimosine Drugs 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 101150029137 mutY gene Proteins 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
• SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
• GLVRJEJEXGVOMJ-UHFFFAOYSA-N neutral red base Chemical compound C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 GLVRJEJEXGVOMJ-UHFFFAOYSA-N 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
• 229960001907 nitrofurazone Drugs 0.000 description 1
• 230000004987 nonapoptotic effect Effects 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 231100001221 nontumorigenic Toxicity 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 230000007959 normoxia Effects 0.000 description 1
• 230000001293 nucleolytic effect Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 229960002446 octanoic acid Drugs 0.000 description 1
• HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 150000002902 organometallic compounds Chemical class 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 238000005191 phase separation Methods 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 230000009120 phenotypic response Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 208000015768 polyposis Diseases 0.000 description 1
• 239000008057 potassium phosphate buffer Substances 0.000 description 1
• ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 108700042226 ras Genes Proteins 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 239000001044 red dye Substances 0.000 description 1
• 230000025915 regulation of apoptotic process Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 208000015891 sexual disease Diseases 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
• JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 238000012409 standard PCR amplification Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
• 238000003161 three-hybrid assay Methods 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 238000003160 two-hybrid assay Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000007332 vesicle formation Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 231100000747 viability assay Toxicity 0.000 description 1
• 238000003026 viability measurement method Methods 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1